Bladder Cancer Weekly

September 23, 2024

Videos

Peer-to-Peer Clinical Conversations

Bladder Cancer Breakthroughs in SunRISe-1, AMBASSADOR, and VOLGA Trials - Maria De Santis

Maria De Santis

Alicia Morgans interviews Maria De Santis about three studies: the SunRISe-1 trial for non-muscle-invasive bladder cancer, the AMBASSADOR study on adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and the VOLGA trial exploring ctDNA clearance as a biomarker.

Harnessing Artifical Intelligence in Bladder Cancer: Digital Tools for Enhanced Diagnosis and Treatment - David McConkey

David McConkey

David McConkey discusses the application of artificial intelligence (AI) in bladder cancer research, focusing on AI pathology.

Beyond the Abstracts

A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape - Beyond the Abstract

Survival of Metastatic Urothelial Carcinoma of Urinary Bladder According to Number and Location of Visceral Metastases - Beyond the Abstract

Conference Coverage

IBCN 2024: Dynamic Monitoring of Circulating Tumor DNA to Predict Prognosis in Muscle-Invasive Bladder Cancer Patients After Radical Cystectomy

IBCN 2024: Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients with Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder: Results from the Multicenter OPTIMUS Umbrella Study

IBCN 2024: Undetectable ctDNA Status Before Radical Cystectomy Predicts Improved Outcomes

IBCN 2024: Keynote Lecture: Inferring Tumor Evolution from Single-Cell Data

IBCN 2024: Elucidating the Response Rates to Additional BCG: Implications for Clinical Trial Design

IBCN 2024: Comprehensive Genomic Characterization of Early Stage Bladder Cancer

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.

Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review.

TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods.

APPRAISE-AI Tool for Quantitative Evaluation of AI Studies for Clinical Decision Support.

Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.

Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials.

Investigating the association between blue light cystoscopy utilization and social determinants of health.

Diagnostic accuracy of cytology and urine methylation test in patients with non-muscle invasive bladder cancer: a systematic review and meta-analysis.

Implementation of Cone Beam Computed Tomography-Guided Online Adaptive Radiotherapy for Challenging Trimodal Therapy in Bladder Preservation: A Report of Two Cases.

Topography and Lateralization of Nodal Metastases in Muscle-Invasive Bladder Cancer Using Super-Extended Pelvic Lymph Node Dissection with the Sentinel Lymph Node Technique.

Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT.

An evaluation of durvalumab across the spectrum of urothelial carcinoma.

The Feasibility and Efficacy of Multiparametric MRI for Staging Bladder Cancer - Expert Commentary

Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer.

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.

The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: A contemporary analysis.

"…I Wish Someone Told Me About That…": A Qualitative Assessment of the Educational Needs of Patients Undergoing Cystectomy.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC